IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 25027363 |
| CHEMBL ID | 538867 |
| CHEBI ID | 177425 |
| SCHEMBL ID | 421999 |
| MeSH ID | M0536706 |
| Synonym |
|---|
| patidegib |
| 1037210-93-7 |
| n-[(3r,3'r,3'as,4ar,6's,6ar,6bs,7'ar,9s,12as,12bs)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3h-uro[3,2-b]pyridine]-3-yl]methanesulonamide |
| CHEBI:177425 |
| ip9 free base |
| CHEMBL538867 , |
| fin-5 |
| ipi 926 |
| ip-9 |
| ipi-926 free base |
| ipi-926 |
| saridegib |
| n-((2s,3r,3as,3''r,4a''r,6s,6a''r,6b''s,7ar,12a''s,12b''s)-3,6,11'',12b''-tetramethyl-2'',3a,3'',4,4'',4a'',5,5'',6,6'',6a'',6b'',7,7a,7'',8'',10'',12'',12a'',12b''-icosahydro-1''h,3h-spiro[furo[3,2-b]pyridine-2,9''-naphtho[2,1-a]azulene]-3''-yl)methanesu |
| bdbm50293788 |
| D10324 |
| patidegib (usan) |
| jt96fpu35x , |
| saridegib [rescinded usan] |
| unii-jt96fpu35x |
| methanesulfonamide, n-((2s,3r,3'r,3as,4'ar,6s,6'ar,6'bs,7ar,12'as,12'bs)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3h),9'(1'h)-naphth(2,1-a)azulen)-3'-yl)- |
| who 9619 |
| patidegib [usan:inn] |
| gtpl8198 |
| n-[(3r,3'r,3'as,4ar,6's,6ar,6bs,7'ar,9s,12as,12bs)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3h-furo[3,2-b]pyridine]-3-yl]methanesulfonamide |
| SCHEMBL421999 |
| patidegib [who-dd] |
| methanesulfonamide, n-((2s,3r,3'r,3as,4'ar,6s,6'ar,6'bs,7ar,12'as,12'bs)-2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3h),9'(1'h)-naphth(2,1-a)azulen)-3'-yl)- |
| patidegib [inn] |
| patidegib [usan] |
| HY-16587 |
| CS-0007501 |
| DTXSID40146032 |
| AKOS027326808 |
| DB12655 |
| n-((2s,3r,3as,3'r,4a'r,6s,6a'r,6b's,7ar,12a's,12b's)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'h,3h-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulen]-3'-yl)methanesulfonamide |
| Q15426668 |
| saridegib (ipi-926; patidegib) |
| MS-29382 |
| EX-A7972 |
| Class | Description |
|---|---|
| piperidines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 14.7403 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 14.7403 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Smoothened homolog | Homo sapiens (human) | IC50 (µMol) | 0.0014 | 0.0004 | 0.1640 | 1.5000 | AID420893 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytokine activity | Interferon beta | Homo sapiens (human) |
| cytokine receptor binding | Interferon beta | Homo sapiens (human) |
| type I interferon receptor binding | Interferon beta | Homo sapiens (human) |
| protein binding | Interferon beta | Homo sapiens (human) |
| chloramphenicol O-acetyltransferase activity | Interferon beta | Homo sapiens (human) |
| cAMP-dependent protein kinase inhibitor activity | Smoothened homolog | Homo sapiens (human) |
| G protein-coupled receptor activity | Smoothened homolog | Homo sapiens (human) |
| patched binding | Smoothened homolog | Homo sapiens (human) |
| protein binding | Smoothened homolog | Homo sapiens (human) |
| oxysterol binding | Smoothened homolog | Homo sapiens (human) |
| protein kinase A catalytic subunit binding | Smoothened homolog | Homo sapiens (human) |
| protein sequestering activity | Smoothened homolog | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID420874 | Volume of distribution in CD1 mouse at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420871 | Plasma clearance in Sprague-Dawley rat at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420883 | Antitumor activity against Ptc+/- Hic+/- mouse B837Tx cells allografted in NOD/SCID mouse assessed as median time to unmeasurable tumor volume at 40 mg/kg, po administered daily for 21 days | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420867 | Oral bioavailability in Sprague-Dawley rat at 5 mg/kg | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420865 | Metabolic stability in human liver microsomes assessed as half life at 500 nM | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420882 | Toxicity in po dosed Ptc+/- Hic+/- mouse B837Tx cells allografted NOD/SCID mouse assessed as maximum tolerated dose after 5 days | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420869 | Oral bioavailability in cynomolgus monkey at 4 mg/kg | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420872 | Plasma clearance in Beagle dog at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420877 | Volume of distribution in cynomolgus monkey at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420891 | Antitumor activity against Ptc+/- Hic+/- mouse B837Tx cells allografted in NOD/SCID mouse assessed as effect on recurrence rate on post treatment at 40 mg/kg, po administered daily for 21 days | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420881 | Elimination half life in cynomolgus monkey at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420873 | Plasma clearance in cynomolgus monkey at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420868 | Oral bioavailability in Beagle dog at 4 mg/kg | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420870 | Plasma clearance in CD1 mouse at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420875 | Volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420866 | Oral bioavailability in CD1 mouse at 5 mg/kg | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420887 | Antitumor activity against Ptc+/- Hic+/- mouse B837Tx cells allografted in NOD/SCID mouse assessed as tumor-free interval on 21 days post treatment at 40 mg/kg, po administered daily for 21 days | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420864 | Inhibition of HedgeHog pathway in mouse C3H10T1/2 cells assessed as inhibition of 20-(S)-hydroxysterol/22-(S)-hydroxysterol-induced osteoblastic differentiation after 72 hrs by Gli-luc reporter assay | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420880 | Elimination half life in Beagle dog at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420893 | Inhibition of human recombinant SMO expressed in mouse C3H10T1/2 cells assessed as inhibition of association of BODIPY-cyclopamine | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420876 | Volume of distribution in Beagle dog at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420879 | Elimination half life in Sprague-Dawley rat at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID420878 | Elimination half life in CD1 mouse at 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1345944 | Human SMO (Class Frizzled GPCRs) | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (12.50%) | 5.53% |
| Reviews | 3 (12.50%) | 6.00% |
| Case Studies | 1 (4.17%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (70.83%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||